vs
Adtalem Global Education Inc.（ATGE）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $503.4M、Adtalem Global Education Inc.の約1.5倍）。Adtalem Global Education Inc.の純利益率が高く（15.2% vs 12.7%、差は2.4%）。Adtalem Global Education Inc.の前年同期比売上増加率が高い（12.4% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $15.1M）。過去8四半期でAdtalem Global Education Inc.の売上複合成長率が高い（10.4% vs 9.0%）
Adtalem Global Education Inc.は米国イリノイ州シカゴに本拠を置く営利目的の高等教育運営企業で、カリブ海アメリカ大学医学部、チェンバレン大学、ロス大学医学部、ロス大学獣医学部、ウォルデン大学などの教育機関を運営し、医療・看護をはじめとする専門分野の教育サービスを提供しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
ATGE vs RVTY — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $503.4M | $772.1M |
| 純利益 | $76.4M | $98.4M |
| 粗利率 | 59.2% | — |
| 営業利益率 | 22.1% | 14.5% |
| 純利益率 | 15.2% | 12.7% |
| 売上前年比 | 12.4% | 5.9% |
| 純利益前年比 | 0.7% | 3.9% |
| EPS（希薄化後） | $2.11 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $503.4M | $772.1M | ||
| Q3 25 | $462.3M | $698.9M | ||
| Q2 25 | $457.1M | $720.3M | ||
| Q1 25 | $466.1M | $664.8M | ||
| Q4 24 | $447.7M | $729.4M | ||
| Q3 24 | $417.4M | $684.0M | ||
| Q2 24 | $409.9M | $691.7M | ||
| Q1 24 | $412.7M | $649.9M |
| Q4 25 | $76.4M | $98.4M | ||
| Q3 25 | $61.8M | $46.7M | ||
| Q2 25 | $54.2M | $53.9M | ||
| Q1 25 | $60.8M | $42.2M | ||
| Q4 24 | $75.9M | $94.6M | ||
| Q3 24 | $46.2M | $94.4M | ||
| Q2 24 | $49.4M | $55.4M | ||
| Q1 24 | $36.8M | $26.0M |
| Q4 25 | 59.2% | — | ||
| Q3 25 | 56.6% | 53.6% | ||
| Q2 25 | 56.5% | 54.5% | ||
| Q1 25 | 57.1% | 56.5% | ||
| Q4 24 | 58.3% | — | ||
| Q3 24 | 55.4% | 56.3% | ||
| Q2 24 | 55.5% | 55.7% | ||
| Q1 24 | 57.5% | 54.6% |
| Q4 25 | 22.1% | 14.5% | ||
| Q3 25 | 18.5% | 11.7% | ||
| Q2 25 | 16.8% | 12.6% | ||
| Q1 25 | 19.4% | 10.9% | ||
| Q4 24 | 23.2% | 16.3% | ||
| Q3 24 | 16.8% | 14.3% | ||
| Q2 24 | 16.7% | 12.4% | ||
| Q1 24 | 15.0% | 6.8% |
| Q4 25 | 15.2% | 12.7% | ||
| Q3 25 | 13.4% | 6.7% | ||
| Q2 25 | 11.9% | 7.5% | ||
| Q1 25 | 13.1% | 6.4% | ||
| Q4 24 | 16.9% | 13.0% | ||
| Q3 24 | 11.1% | 13.8% | ||
| Q2 24 | 12.1% | 8.0% | ||
| Q1 24 | 8.9% | 4.0% |
| Q4 25 | $2.11 | $0.86 | ||
| Q3 25 | $1.67 | $0.40 | ||
| Q2 25 | $1.43 | $0.46 | ||
| Q1 25 | $1.59 | $0.35 | ||
| Q4 24 | $1.98 | $0.77 | ||
| Q3 24 | $1.18 | $0.77 | ||
| Q2 24 | $1.23 | $0.45 | ||
| Q1 24 | $0.93 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $56.3M | $919.9M |
| 総負債低いほど良い | $504.3M | — |
| 株主資本純資産 | $1.4B | $7.3B |
| 総資産 | $2.6B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $56.3M | $919.9M | ||
| Q3 25 | $264.7M | $931.4M | ||
| Q2 25 | $199.6M | $991.8M | ||
| Q1 25 | $219.0M | $1.1B | ||
| Q4 24 | $194.0M | $1.2B | ||
| Q3 24 | $264.8M | $1.2B | ||
| Q2 24 | $219.3M | $2.0B | ||
| Q1 24 | $179.8M | $1.7B |
| Q4 25 | $504.3M | — | ||
| Q3 25 | $553.2M | — | ||
| Q2 25 | $552.7M | — | ||
| Q1 25 | $552.2M | — | ||
| Q4 24 | $649.9M | — | ||
| Q3 24 | $649.3M | — | ||
| Q2 24 | $648.7M | — | ||
| Q1 24 | $648.1M | — |
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.3B | $7.8B |
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.8B | $12.4B | ||
| Q4 24 | $2.7B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.39× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.49× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $29.7M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $15.1M | $161.8M |
| FCFマージンFCF / 売上 | 3.0% | 21.0% |
| 設備投資強度設備投資 / 売上 | 2.9% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 0.39× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $368.0M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.7M | $182.0M | ||
| Q3 25 | $130.5M | $138.5M | ||
| Q2 25 | $59.7M | $134.3M | ||
| Q1 25 | $207.9M | $128.2M | ||
| Q4 24 | $-19.0M | $174.2M | ||
| Q3 24 | $89.3M | $147.9M | ||
| Q2 24 | $40.6M | $158.6M | ||
| Q1 24 | $162.6M | $147.6M |
| Q4 25 | $15.1M | $161.8M | ||
| Q3 25 | $114.5M | $120.0M | ||
| Q2 25 | $40.7M | $115.5M | ||
| Q1 25 | $197.7M | $112.2M | ||
| Q4 24 | $-29.7M | $149.8M | ||
| Q3 24 | $78.9M | $125.6M | ||
| Q2 24 | $37.4M | $136.6M | ||
| Q1 24 | $140.9M | $129.7M |
| Q4 25 | 3.0% | 21.0% | ||
| Q3 25 | 24.8% | 17.2% | ||
| Q2 25 | 8.9% | 16.0% | ||
| Q1 25 | 42.4% | 16.9% | ||
| Q4 24 | -6.6% | 20.5% | ||
| Q3 24 | 18.9% | 18.4% | ||
| Q2 24 | 9.1% | 19.7% | ||
| Q1 24 | 34.2% | 20.0% |
| Q4 25 | 2.9% | 2.6% | ||
| Q3 25 | 3.5% | 2.6% | ||
| Q2 25 | 4.2% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 2.4% | 3.4% | ||
| Q3 24 | 2.5% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 5.3% | 2.7% |
| Q4 25 | 0.39× | 1.85× | ||
| Q3 25 | 2.11× | 2.97× | ||
| Q2 25 | 1.10× | 2.49× | ||
| Q1 25 | 3.42× | 3.03× | ||
| Q4 24 | -0.25× | 1.84× | ||
| Q3 24 | 1.93× | 1.57× | ||
| Q2 24 | 0.82× | 2.87× | ||
| Q1 24 | 4.42× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ATGE
| Walden University Segment | $217.6M | 43% |
| Chamberlain University Segment | $183.8M | 37% |
| Medical And Veterinary | $102.0M | 20% |
| Other Services | $1.6M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
